<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37550">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617693</url>
  </required_header>
  <id_info>
    <org_study_id>INS-4186</org_study_id>
    <secondary_id>U1111-1160-2987</secondary_id>
    <nct_id>NCT02617693</nct_id>
  </id_info>
  <brief_title>Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes</brief_title>
  <acronym>Jom Mama</acronym>
  <official_title>Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this study is to assess the efficacy of a
      pre-pregnancy life style intervention to reduce the risk of diabetes and prediabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in waist circumference</measure>
    <time_frame>Months 0-8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BMI (Body Mass Index)</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist-to-height ratio (WHtR)</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist-to-hip ratio</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Glycosylated haemoglobin))</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the fasting lipid profile (total cholesterol [TC], low density lipoprotein cholesterol[LDL-C], high density lipoprotein cholesterol[HDL-C], triglycerides [TG])</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure (SBP (systolic blood pressure) and DBP(diastolic blood pressure))</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the level of health literacy, as measured by the European Health Literacy Survey Questionnaire (HLC-EU-Q)</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dietary intake, as measured by the Frequency Food Questionnaire (FFQ) that is used in National Health Surveys in Malaysia</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dietary intake, as measured by a Frequency Food Questionnaire (FFQ)</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity and sedentary behaviour, as measured by the International Physical Activity Questionnaire (IPAQ) used in National Health Surveys in Malaysia</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress levels, as measured by the Depression Anxiety and Stress Scale 21-items (DASS-21) used in National Health Surveys in Malaysia</measure>
    <time_frame>Month 0, Month 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Life style intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform</description>
    <arm_group_label>Life style intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Nulliparity

          -  Not pregnant at the time of signing informed consent

          -  Own a smartphone with either Android system version 4.1 and above or iOS system 7.0
             and above with internet access

        Exclusion Criteria:

          -  Female subject undergoing treatment for type 1 or 2 diabetes mellitus

          -  Subjects not residing in the district of Seremban
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seremban, Negeri Sembilan</city>
        <zip>70400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 27, 2016</lastchanged_date>
  <firstreceived_date>November 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
